Martinez Juan-Carlos, Otley Clark C, Euvrard Sylvie, Arpey Christopher J, Stasko Thomas
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Dermatol Surg. 2004 Apr;30(4 Pt 2):662-6. doi: 10.1111/j.1524-4725.2004.30153.x.
Organ transplant recipients receiving immunosuppressive medications are at increased risk of cutaneous malignancies.
We sought to determine the complications associated with systemic retinoid therapy in severely affected organ transplant recipients receiving treatment before or during the course of metastatic squamous cell carcinoma.
This was a collaborative retrospective study of solid organ transplant recipients treated with systemic retinoids for severe squamous cell carcinoma, with subjective analysis of complications associated with treatment.
Complications and intolerance of systemic retinoid therapy were common, necessitating discontinuation of therapy in six of eight cases.
This subset of transplant patients, severely affected by skin cancer, appeared to be less able to tolerate systemic retinoid therapy than patients in formal clinical trials. Intolerance of adverse effects in this context suggests the need for novel approaches with these challenging patients.
接受免疫抑制药物治疗的器官移植受者患皮肤恶性肿瘤的风险增加。
我们试图确定在转移性鳞状细胞癌病程之前或期间接受治疗的严重受影响器官移植受者中，与全身维甲酸治疗相关的并发症。
这是一项对接受全身维甲酸治疗严重鳞状细胞癌的实体器官移植受者进行的合作回顾性研究，对与治疗相关的并发症进行主观分析。
全身维甲酸治疗的并发症和不耐受情况很常见，八例中有六例需要停药。
与正式临床试验中的患者相比，这一受皮肤癌严重影响的移植患者亚组似乎更难以耐受全身维甲酸治疗。在这种情况下对不良反应的不耐受表明，对于这些具有挑战性的患者需要采用新的方法。
